Pathogenesis of the ductal pancreatic adenocarcinoma: Implications for future therapies?;Pathogenese des pankreaskarzinoms: Bereits konsequenzen für künftige therapeutische ansätze?

Internist

Volumn 46, Issue 2, 2005, Pages 157-165

  Schneider, G ^a   Schmid, R M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Carcinogenesis; Ductal pancreatic adenocarcinoma; Oncogenes; Tumorprogression; Tumorsuppressorgenes

Indexed keywords

APOPTOSIS; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; PANCREAS CARCINOMA; PANCREAS CELL; PATHOGENESIS; REVIEW; SURVIVAL;

APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; GENES, CDC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM INVASIVENESS; PANCREAS; PANCREATIC NEOPLASMS;

EID: 14244264190     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-004-1330-4     Document Type: Review

References (30)

1. Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clin Cancer Res 6: 2969-2972
2. Hansel DE, Kern SE, Hruban RH (2003) Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 4: 237-256
3. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363: 1049-1057
4. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
5. Rozenblum E, Schutte M, Goggins M et al. (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57: 1731-1734
6. Plath T, Peters M, Detjen K et al. (2002) Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J Natl Cancer Inst 94: 129-142
7. Schneider G, Schmid RM (2003) Genetic alterations in pancreatic carcinoma. Mol Cancer 2: 15
8. Scholz A, Heinze S, Detjen KM et al. (2003) Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125: 891-905
9. Juuti A, Nordling S, Louhimo J, Lundin J, von Boguslawski K, Haglund C (2003) Loss of p27 expression is associated with poor prognosis in stage I-II pancreatic cancer. Oncology 65: 371-377
10. Abdelrahim M, Smith R, Burghardt R, Safe S (2004) Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64: 6740-6749
11. Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288
12. Okada H, Mak TW (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4: 592-603
13. Schulze-Bergkamen H, Krammer PH (2004) Apoptosis in cancer - implications for therapy. Semin Oncol 31: 90-119
14. Gerhard MC, Schmid RM, Hacker G (2002) Analysis of the cytochrome c-dependent apoptosis apparatus in cells from human pancreatic carcinoma. Br J Cancer 86: 893-898
15. Westphal S, Kalthoff H (2003) Apoptosis: targets in pancreatic cancer. Mol Cancer 2: 6
16. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501
17. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ (2003) Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110-2115
18. Fahy BN, Schlieman M, Virudachalam S, Bold RJ (2003) AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 89: 391-397
19. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ (2004) Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198: 591-599
20. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310
21. Arlt A, Vorndamm J, Muerkoster S, Yu H, Schmidt WE, Folsch UR, Schafer H (2002) Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62: 910-916
22. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM (2003) Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 105: 735-746
23. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM (2002) Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123: 2052-2063
24. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454
25. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H (2003) Invasion and metastasis in pancreatic cancer. Mol Cancer 2: 14
26. Ellenrieder V, Hendler SF, Boeck W et al. (2001) Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61: 4222-4228
27. Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD (2002) Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 109: 1437-1444
28. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L (2003) VEGF-receptor signal transduction. Trends Biochem Sci 28: 488-494
29. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47
30. Zhong H, De Marzo AM, Laughner E et al. (1999) Overexpression of hypoxia-induciblefactor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835